What TB-500 is and how it relates to thymosin beta-4
Thymosin beta-4 (Tb4) is a 43-amino acid, 5 kDa protein found in most mammalian cells. It is among the most abundant intracellular peptides, with particularly high concentrations in platelets and immune cells. At sites of tissue injury, Tb4 is released from activated platelets as part of the wound response.
TB-500 is a synthetic peptide corresponding to amino acids 17-23 of Tb4, with the core sequence LKKTETQ. This fragment covers the actin-binding domain responsible for cell migration and most wound-healing activity documented in the literature. Mass spectrometric analysis of equine doping control samples confirmed that TB-500 is a synthetic version of this active region, detectable in horse urine and plasma after administration (Gmeiner et al., Drug Test Anal., 2013).
Full-length Tb4 also contains an N-terminal tetrapeptide, Ac-SDKP, that is absent from the 17-amino acid TB-500 fragment. Ac-SDKP has distinct activity: it suppresses TGF-beta-driven fibrosis and reduces pro-inflammatory cytokine signaling through a pathway separate from actin binding. No published study has directly compared wound outcomes for the fragment versus full-length Tb4 under controlled conditions, so the biological equivalence cannot be assumed.
How thymosin beta-4 regulates actin and cell migration
Tb4 is the primary G-actin sequestering protein in eukaryotic cells, binding free monomeric actin in a 1:1 stoichiometric ratio and maintaining a reserve pool of unpolymerized actin for rapid cytoskeletal remodeling. When cells need to migrate quickly, as keratinocytes do during wound closure, this reserve pool supports fast actin polymerization at the leading edge. Goldstein, Hannappel, and Kleinman traced this mechanism in detail in a 2005 review in Trends in Molecular Medicine, connecting actin sequestration to enhanced migration in endothelial cells, keratinocytes, and cardiac muscle cells (Goldstein, Hannappel, Kleinman, Trends Mol Med., 2005).
Beyond actin regulation, Tb4 forms a functional signaling complex with PINCH-1 and integrin-linked kinase (ILK). This complex activates Akt/PKB, a serine-threonine kinase central to cell survival signaling. The ILK-Akt axis mediates the anti-apoptotic effects of Tb4 in cardiomyocytes and contributes to the anti-inflammatory activity observed in wound tissue.
The two activities, actin sequestration and ILK-Akt signaling, operate through different parts of the Tb4 molecule. TB-500 retains the actin-binding LKKTETQ segment, but whether the 17-amino acid fragment forms the same ILK-Akt complex as full-length Tb4 has not been confirmed in published cell biology studies.
Wound healing: the TB-500 research evidence base
The wound healing literature for Tb4 is the strongest in the field. A 1999 study in the Journal of Investigative Dermatology measured the effect of Tb4 in a mouse dermal wound model. Topical or intraperitoneal Tb4 increased reepithelialization by 42% at day 4 and by 61% at day 7, compared with saline controls. Keratinocyte migration in vitro was stimulated 2 to 3 fold at Tb4 concentrations as low as 10 picograms. Collagen deposition and angiogenesis were both elevated in treated wounds relative to controls (Malinda et al., J Invest Dermatol., 1999, murine wound model).
Human clinical data comes from Phase 2 trials run by RegeneRx Biopharmaceuticals. The trials enrolled patients with pressure ulcers, venous stasis ulcers, and epidermolysis bullosa wounds. Tb4 accelerated the rate of repair across all three wound types, with acceptable safety and tolerability. A 2012 review summarizing these Phase 2 outcomes alongside the supporting animal model data was published by Treadwell, Kleinman, Crockford, Hardy, Guarnera, and Goldstein in the Annals of the New York Academy of Sciences (Treadwell et al., Ann N Y Acad Sci., 2012, Phase 2 trials). No Phase 3 dermal wound trial has since been completed.
A broader 2012 review by Goldstein and colleagues covered Tb4 activity in diabetic and aged animal wound models, in burn models, and in corneal wound healing, where the peptide accelerated re-epithelialization across multiple animal species. RegeneRx also ran a separate Phase 2 corneal trial (NCT00598871) and reported accelerated healing in neurotrophic keratopathy (Goldstein, Hannappel, Sosne, Kleinman, Expert Opin Biol Ther., 2012).
Cardiac tissue studies
Thymosin beta-4 has been studied in cardiac injury models since the mid-2000s. A mouse coronary artery ligation study published in 2007 in the Annals of the New York Academy of Sciences showed that Tb4 treatment upregulated ILK and Akt activity in cardiac tissue, enhanced early cardiomyocyte survival, and improved post-infarction cardiac function compared with vehicle controls. The study concluded that the cardioprotective effects are mechanistically dependent on the ILK-Akt pathway, separate from the actin-sequestering function (Smart et al., Ann N Y Acad Sci., 2007, murine MI model).
Subsequent work from the same group showed that Tb4 secreted by myocardial cells acts as a paracrine signal to epicardium-derived progenitor cells, stimulating inward migration and contributing to coronary neovascularization after injury. All cardiac findings to date are from rodent models. No cardiac Phase 2 or Phase 3 trial of thymosin beta-4 or TB-500 is currently registered on ClinicalTrials.gov.
Equine medicine and the doping context
TB-500 first appeared as a product name in equine sports medicine, where it was used to support tendon and muscle recovery in racehorses. The 2013 Gmeiner study arose specifically because anti-doping regulators needed a mass spectrometry method to detect prior TB-500 administration in horses. That study also provided the most rigorous published confirmation that TB-500 corresponds to the LKKTETQ fragment of Tb4. No controlled equine trial of TB-500 as a distinct compound has been published; the veterinary rationale rests on extrapolation from full-length Tb4 animal studies.
WADA added thymosin beta-4 and its fragments to the prohibited list under S2.2 (peptide hormones, growth factors, and related substances) in 2012. The prohibition applies to competitive athletics and does not affect laboratory research use. In Indonesia, thymosin beta-4 and TB-500 are not classified as controlled substances for research purposes under BPOM guidelines on biological research materials.
Research limitations and the BPC-157 comparison
The clearest evidence base covers dermal wound healing: quantified data from rodent models and Phase 2 human data for three categories of chronic wound. The cardiac and corneal findings are less developed. The gap between full-length Tb4 and the shorter TB-500 fragment is a genuine limitation that the published literature does not address directly.
TB-500 is frequently studied alongside BPC-157, which accounts for the "TB-500 BPC-157 stack" that appears in the research literature. The two compounds are structurally unrelated: BPC-157 is a 15-amino acid synthetic fragment of a gastric protein, while TB-500 derives from an actin-binding protein. Their proposed mechanisms do not overlap. For the BPC-157 evidence base, see the BPC-157 research overview. Both peptides are listed in the BPC-157 and TB-500 compound catalog.
For reconstitution and handling, TB-500 follows the standard lyophilized peptide protocol. Procedures are covered in the reconstitution guide. Dosing volumes for specific research concentrations can be verified with the dosing calculator.